- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06649812
Test de l'efficacité d'une thérapie ciblée combinée (ViPOR) pour les patients atteints de lymphome agressif à cellules B récidivant et/ou réfractaire
Une étude de phase 2 sur le vénétoclax, l'ibrutinib, la prednisone, l'obinutuzumab et le Revlimid (ViPOR) dans le lymphome diffus à grandes cellules B (DLBCL) en rechute ou réfractaire et le lymphome diffus à grandes cellules B de haut grade avec réarrangements MYC et BCL2 (HGBCL -DH-BCL2)
This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (relapsed) and/or that has not responded to previous treatment (refractory). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Ibrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers at abnormal levels. This may help keep cancer cells from growing and spreading. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Obinutuzumab, a monoclonal antibody, binds to a protein called CD20, which is found on B cells and some types of leukemia and lymphoma cells. Obinutuzumab may block CD20 and help the immune system kill cancer cells. Revlimid, a type of anti-angiogenesis agent and a type of immunomodulating agent, may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that cancers need to grow. ViPOR may be an effective treatment option for patients with relapsed and/or refractory CD10 negative DLBCL and high-grade B-cell lymphoma with MYC and BCL2 rearrangements.
Aperçu de l'étude
Statut
Les conditions
- Lymphome diffus à grandes cellules B récurrent
- Lymphome diffus à grandes cellules B réfractaire
- Lymphome B récurrent de haut grade avec réarrangements MYC, BCL2 et BCL6
- Lymphome réfractaire à cellules B de haut grade avec réarrangements MYC, BCL2 et BCL6
- Lymphome diffus à grandes cellules B récurrent, non spécifié ailleurs
- Lymphome B récurrent de haut grade avec réarrangements MYC et BCL2 ou BCL6
- Lymphome diffus à grandes cellules B réfractaire, non spécifié ailleurs
- Lymphome réfractaire à cellules B de haut grade avec réarrangements MYC et BCL2 ou BCL6
- Lymphome T récurrent/riche en histiocytes à grandes cellules B
- Lymphome T réfractaire/riche en histiocytes à grandes cellules B
- Lymphome à cellules B récurrent de haut grade, non spécifié ailleurs
- Lymphome à cellules B réfractaire de haut grade, non spécifié ailleurs
- Lymphome diffus récurrent à grandes cellules B de type centre germinal
- Lymphome diffus à grandes cellules B réfractaire de type cellule B du centre germinal
- Lymphome à cellules B de haut grade avec réarrangements MYC et BCL6
Intervention / Traitement
- Médicament: Prednisone
- Médicament: Lenalidomide
- Procédure: Biospecimen Collection
- Procédure: Computed Tomography
- Procédure: Magnetic Resonance Imaging
- Procédure: Bone Marrow Aspiration
- Procédure: Bone Marrow Biopsy
- Médicament: Ibrutinib
- Procédure: Positron Emission Tomography
- Médicament: Venetoclax
- Biologique: Obinutuzumab
- Procédure: Biopsy Procedure
Description détaillée
PRIMARY OBJECTIVES:
I. To evaluate the complete response (CR) rate of ViPOR in relapsed/refractory (R/R):
Ia. CD10-negative DLBCL; and Ib. CD10-positive or negative high-grade B-cell lymphoma (HGBCL) with MYC and BCL2 (with or without BCL6) translocations (HGBCL-double hit [DH]-BCL2).
SECONDARY OBJECTIVES:
I. To evaluate the complete response (CR) rate of ViPOR in relapsed/refractory (R/R):
Ia. CD10-negative activated B-cell (ABC) DLBCL; and Ib. CD10-negative non-ABC (i.e., unclassified or germinal center B-cell [GCB]) DLBCL.
II. To evaluate the overall response rate (ORR), duration of response (DOR), event-free survival (EFS), time to progression (TTP), progression-free survival (PFS), overall survival (OS), and the safety & toxicity profile of ViPOR in relapsed/refractory (R/R):
IIa. CD10-negative ABC DLBCL; and IIb. CD10-negative non-ABC (i.e., unclassified or GCB) DLBCL; and IIc. CD10-positive or negative HGBCL-DH-BCL2.
EXPLORATORY OBJECTIVES:
I. To assess response and outcome to ViPOR based on molecular DLBCL subtype by cell-of-origin (COO) testing using Lymph2Cx gene-expression profiling (GEP).
II. To assess response and outcome to ViPOR based on genetic DLBCL subtype by LymphGen classification using whole exome sequencing (WES), whole genome sequencing (WGS), and ribonucleic acid (RNA)-sequencing (RNA-seq).
III. To determine other molecular correlates of response or resistance to ViPOR therapy.
IV. To determine early molecular correlates of response or resistance as well as the rate of complete molecular remission, as determined by assays for circulating-tumor deoxyribonucleic acid (DNA) (ctDNA).
OUTLINE:
Patients receive venetoclax orally (PO) once daily (QD) on days 2-14, ibrutinib PO QD on days 1-14, prednisone PO QD on days 1-7, obinutuzumab intravenously (IV) on days 1 and 2, and lenalidomide (Revlimid) PO QD on days 1-14 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, positron emission tomography (PET), computed tomography (CT) and/or magnetic resonance imaging (MRI) and optional tumor biopsy and bone marrow aspiration and biopsy throughout the study.
After completion of study treatment, patients are followed up every 6 months for 2 years, yearly during years 3-5, and then for survival for up to 10 years from the date of registration.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Arizona
-
Tucson, Arizona, États-Unis, 85719
- Actif, ne recrute pas
- Banner University Medical Center - Tucson
-
Tucson, Arizona, États-Unis, 85719
- Actif, ne recrute pas
- University of Arizona Cancer Center-North Campus
-
-
California
-
Los Angeles, California, États-Unis, 90048
- Recrutement
- Cedars-Sinai Medical Center
-
Chercheur principal:
- Justin M. Darrah
-
Contact:
- Site Public Contact
- Numéro de téléphone: 310-423-2133
- E-mail: Cancer.trial.info@cshs.org
-
-
Connecticut
-
Derby, Connecticut, États-Unis, 06418
- Recrutement
- Smilow Cancer Hospital-Derby Care Center
-
Chercheur principal:
- Shalin Kothari
-
Contact:
- Site Public Contact
- Numéro de téléphone: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Guilford, Connecticut, États-Unis, 06437
- Recrutement
- Smilow Cancer Hospital Care Center - Guilford
-
Chercheur principal:
- Shalin Kothari
-
Contact:
- Site Public Contact
- Numéro de téléphone: 203-785-5702
- E-mail: canceranswers@yale.edu
-
New Haven, Connecticut, États-Unis, 06520
- Recrutement
- Yale University
-
Chercheur principal:
- Shalin Kothari
-
Contact:
- Site Public Contact
- Numéro de téléphone: 203-785-5702
- E-mail: canceranswers@yale.edu
-
-
Idaho
-
Coeur d'Alene, Idaho, États-Unis, 83814
- Recrutement
- Kootenai Health - Coeur d'Alene
-
Chercheur principal:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Numéro de téléphone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Post Falls, Idaho, États-Unis, 83854
- Recrutement
- Kootenai Clinic Cancer Services - Post Falls
-
Chercheur principal:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Numéro de téléphone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Sandpoint, Idaho, États-Unis, 83864
- Recrutement
- Kootenai Clinic Cancer Services - Sandpoint
-
Chercheur principal:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Numéro de téléphone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Recrutement
- Northwestern University
-
Contact:
- Site Public Contact
- Numéro de téléphone: 312-695-1301
- E-mail: cancer@northwestern.edu
-
Chercheur principal:
- Reem Karmali
-
Danville, Illinois, États-Unis, 61832
- Suspendu
- Carle at The Riverfront
-
DeKalb, Illinois, États-Unis, 60115
- Recrutement
- Northwestern Medicine Cancer Center Kishwaukee
-
Contact:
- Site Public Contact
- Numéro de téléphone: 630-352-5360
- E-mail: Donald.Smith3@nm.org
-
Chercheur principal:
- Reem Karmali
-
Effingham, Illinois, États-Unis, 62401
- Suspendu
- Carle Physician Group-Effingham
-
Geneva, Illinois, États-Unis, 60134
- Recrutement
- Northwestern Medicine Cancer Center Delnor
-
Contact:
- Site Public Contact
- Numéro de téléphone: 630-352-5360
- E-mail: Donald.Smith3@nm.org
-
Chercheur principal:
- Reem Karmali
-
Glenview, Illinois, États-Unis, 60026
- Recrutement
- Northwestern Medicine Glenview Outpatient Center
-
Chercheur principal:
- Reem Karmali
-
Contact:
- Site Public Contact
- Numéro de téléphone: 312-695-1102
-
Grayslake, Illinois, États-Unis, 60030
- Recrutement
- Northwestern Medicine Grayslake Outpatient Center
-
Chercheur principal:
- Reem Karmali
-
Contact:
- Site Public Contact
- Numéro de téléphone: 312-695-1102
-
Lake Forest, Illinois, États-Unis, 60045
- Recrutement
- Northwestern Medicine Lake Forest Hospital
-
Chercheur principal:
- Reem Karmali
-
Contact:
- Site Public Contact
- E-mail: cancertrials@northwestern.edu
-
Mattoon, Illinois, États-Unis, 61938
- Suspendu
- Carle Physician Group-Mattoon/Charleston
-
Normal, Illinois, États-Unis, 61761
- Suspendu
- Carle Cancer Institute Normal
-
Normal, Illinois, États-Unis, 61761
- Suspendu
- Carle BroMenn Medical Center
-
Oak Brook, Illinois, États-Unis, 60523
- Recrutement
- Northwestern Medicine Oak Brook
-
Chercheur principal:
- Reem Karmali
-
Contact:
- Site Public Contact
- E-mail: nctnprogram_rhlccc@northwestern.edu
-
Orland Park, Illinois, États-Unis, 60462
- Recrutement
- Northwestern Medicine Orland Park
-
Chercheur principal:
- Reem Karmali
-
Contact:
- Site Public Contact
- E-mail: nctnprogram_rhlccc@northwestern.edu
-
Shiloh, Illinois, États-Unis, 62269
- Recrutement
- Memorial Hospital East
-
Contact:
- Site Public Contact
- Numéro de téléphone: 314-747-9912
- E-mail: dschwab@wustl.edu
-
Chercheur principal:
- Brad S. Kahl
-
Urbana, Illinois, États-Unis, 61801
- Suspendu
- Carle Cancer Center
-
Warrenville, Illinois, États-Unis, 60555
- Recrutement
- Northwestern Medicine Cancer Center Warrenville
-
Contact:
- Site Public Contact
- Numéro de téléphone: 630-352-5360
- E-mail: Donald.Smith3@nm.org
-
Chercheur principal:
- Reem Karmali
-
-
Indiana
-
Crown Point, Indiana, États-Unis, 46307
- Recrutement
- Northwest Cancer Center - Crown Point
-
Chercheur principal:
- Suparna Mantha
-
Contact:
- Site Public Contact
- Numéro de téléphone: 219-836-6879
- E-mail: CancerResearch@powershealth.org
-
Dyer, Indiana, États-Unis, 46311
- Recrutement
- Northwest Oncology LLC
-
Chercheur principal:
- Suparna Mantha
-
Contact:
- Site Public Contact
- Numéro de téléphone: 219-924-8178
-
Hobart, Indiana, États-Unis, 46342
- Recrutement
- Saint Mary Medical Center
-
Chercheur principal:
- Suparna Mantha
-
Contact:
- Site Public Contact
- Numéro de téléphone: 219-836-6875
- E-mail: CancerResearch@COMHS.org
-
Indianapolis, Indiana, États-Unis, 46312
- Recrutement
- Saint Catherine Hospital
-
Chercheur principal:
- Suparna Mantha
-
Contact:
- Site Public Contact
- E-mail: ecog.rss@jimmy.harvard.edu
-
Munster, Indiana, États-Unis, 46321
- Recrutement
- The Community Hospital
-
Chercheur principal:
- Suparna Mantha
-
Contact:
- Site Public Contact
- Numéro de téléphone: 219-836-3349
-
Munster, Indiana, États-Unis, 46321
- Recrutement
- Women's Diagnostic Center - Munster
-
Chercheur principal:
- Suparna Mantha
-
Contact:
- Site Public Contact
- Numéro de téléphone: 219-934-8869
- E-mail: mnicholson@comhs.org
-
Valparaiso, Indiana, États-Unis, 46383
- Recrutement
- Northwest Cancer Center - Valparaiso
-
Chercheur principal:
- Suparna Mantha
-
Contact:
- Site Public Contact
- Numéro de téléphone: 219-836-6875
- E-mail: CancerResearch@COMHS.org
-
-
Iowa
-
Ames, Iowa, États-Unis, 50010
- Recrutement
- Mary Greeley Medical Center
-
Chercheur principal:
- Joseph J. Merchant
-
Contact:
- Site Public Contact
- Numéro de téléphone: 515-956-4132
-
Ames, Iowa, États-Unis, 50010
- Recrutement
- McFarland Clinic - Ames
-
Chercheur principal:
- Joseph J. Merchant
-
Contact:
- Site Public Contact
- Numéro de téléphone: 515-239-4734
- E-mail: ksoder@mcfarlandclinic.com
-
Ankeny, Iowa, États-Unis, 50023
- Recrutement
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Contact:
- Site Public Contact
- Numéro de téléphone: 515-241-3305
-
Chercheur principal:
- Seema Harichand-Herdt
-
Boone, Iowa, États-Unis, 50036
- Suspendu
- McFarland Clinic - Boone
-
Carroll, Iowa, États-Unis, 51401
- Recrutement
- Saint Anthony Regional Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 515-689-7658
- E-mail: sbenson@iora.org
-
Chercheur principal:
- Seema Harichand-Herdt
-
Cedar Rapids, Iowa, États-Unis, 52403
- Recrutement
- Mercy Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 319-365-4673
-
Chercheur principal:
- Deborah W. Wilbur
-
Cedar Rapids, Iowa, États-Unis, 52403
- Recrutement
- Oncology Associates at Mercy Medical Center
-
Chercheur principal:
- Deborah W. Wilbur
-
Contact:
- Site Public Contact
- Numéro de téléphone: 319-363-2690
-
Clive, Iowa, États-Unis, 50325
- Recrutement
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Contact:
- Site Public Contact
- Numéro de téléphone: 515-241-3305
-
Chercheur principal:
- Seema Harichand-Herdt
-
Des Moines, Iowa, États-Unis, 50314
- Recrutement
- Broadlawns Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 515-282-2200
-
Chercheur principal:
- Seema Harichand-Herdt
-
Des Moines, Iowa, États-Unis, 50309
- Recrutement
- Iowa Methodist Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 515-241-6727
-
Chercheur principal:
- Seema Harichand-Herdt
-
Des Moines, Iowa, États-Unis, 50309
- Recrutement
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Contact:
- Site Public Contact
- Numéro de téléphone: 515-241-3305
-
Chercheur principal:
- Seema Harichand-Herdt
-
Des Moines, Iowa, États-Unis, 50314
- Recrutement
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Contact:
- Site Public Contact
- Numéro de téléphone: 515-241-3305
-
Chercheur principal:
- Seema Harichand-Herdt
-
Fort Dodge, Iowa, États-Unis, 50501
- Recrutement
- McFarland Clinic - Trinity Cancer Center
-
Chercheur principal:
- Joseph J. Merchant
-
Contact:
- Site Public Contact
- Numéro de téléphone: 515-956-4132
-
Fort Dodge, Iowa, États-Unis, 50501
- Recrutement
- UI Healthcare Mission Cancer and Blood - Fort Dodge
-
Chercheur principal:
- Seema Harichand-Herdt
-
Contact:
- Site Public Contact
- Numéro de téléphone: 515-282-2921
- E-mail: trials@missioncancer.com
-
Jefferson, Iowa, États-Unis, 50129
- Suspendu
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, États-Unis, 50158
- Recrutement
- McFarland Clinic - Marshalltown
-
Chercheur principal:
- Joseph J. Merchant
-
Contact:
- Site Public Contact
- Numéro de téléphone: 515-956-4132
-
Waukee, Iowa, États-Unis, 50263
- Recrutement
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
Contact:
- Site Public Contact
- Numéro de téléphone: 515-241-3305
-
Chercheur principal:
- Seema Harichand-Herdt
-
-
Louisiana
-
New Orleans, Louisiana, États-Unis, 70121
- Suspendu
- Ochsner Medical Center Jefferson
-
-
Maryland
-
Bethesda, Maryland, États-Unis, 20892
- Recrutement
- National Institutes of Health Clinical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-411-1222
-
Chercheur principal:
- Christopher J. Melani
-
Bethesda, Maryland, États-Unis, 20889-5600
- Recrutement
- Walter Reed National Military Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 301-319-2100
-
Chercheur principal:
- Christin Destefano
-
-
Michigan
-
Escanaba, Michigan, États-Unis, 49829
- Recrutement
- OSF Saint Francis Hospital and Medical Group
-
Chercheur principal:
- Brian L. Burnette
-
Contact:
- Site Public Contact
- Numéro de téléphone: 920-433-8889
- E-mail: WI_research_admin@hshs.org
-
Manistique, Michigan, États-Unis, 49854
- Recrutement
- Schoolcraft Memorial Hospital
-
Chercheur principal:
- Brian L. Burnette
-
Contact:
- Site Public Contact
- Numéro de téléphone: 920-433-8889
- E-mail: WI_research_admin@hshs.org
-
-
Minnesota
-
Brainerd, Minnesota, États-Unis, 56401
- Recrutement
- Essentia Health Saint Joseph's Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Chercheur principal:
- Bret E. Friday
-
Deer River, Minnesota, États-Unis, 56636
- Recrutement
- Essentia Health - Deer River Clinic
-
Contact:
- Site Public Contact
- Numéro de téléphone: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Chercheur principal:
- Bret E. Friday
-
Duluth, Minnesota, États-Unis, 55805
- Recrutement
- Essentia Health Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Chercheur principal:
- Bret E. Friday
-
Hibbing, Minnesota, États-Unis, 55746
- Recrutement
- Essentia Health Hibbing Clinic
-
Chercheur principal:
- Bret E. Friday
-
Contact:
- Site Public Contact
- Numéro de téléphone: 218-786-3308
-
Sandstone, Minnesota, États-Unis, 55072
- Recrutement
- Essentia Health Sandstone
-
Contact:
- Site Public Contact
- Numéro de téléphone: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Chercheur principal:
- Bret E. Friday
-
Virginia, Minnesota, États-Unis, 55792
- Recrutement
- Essentia Health Virginia Clinic
-
Contact:
- Site Public Contact
- Numéro de téléphone: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Chercheur principal:
- Bret E. Friday
-
-
Missouri
-
City of Saint Peters, Missouri, États-Unis, 63376
- Recrutement
- Siteman Cancer Center at Saint Peters Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Chercheur principal:
- Brad S. Kahl
-
Creve Coeur, Missouri, États-Unis, 63141
- Recrutement
- Siteman Cancer Center at West County Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Chercheur principal:
- Brad S. Kahl
-
St Louis, Missouri, États-Unis, 63110
- Recrutement
- Washington University School of Medicine
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Chercheur principal:
- Brad S. Kahl
-
St Louis, Missouri, États-Unis, 63129
- Recrutement
- Siteman Cancer Center-South County
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Chercheur principal:
- Brad S. Kahl
-
St Louis, Missouri, États-Unis, 63136
- Recrutement
- Siteman Cancer Center at Christian Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Chercheur principal:
- Brad S. Kahl
-
-
Montana
-
Anaconda, Montana, États-Unis, 59711
- Suspendu
- Community Hospital of Anaconda
-
Billings, Montana, États-Unis, 59101
- Recrutement
- Billings Clinic Cancer Center
-
Chercheur principal:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-996-2663
- E-mail: research@billingsclinic.org
-
Bozeman, Montana, États-Unis, 59715
- Suspendu
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, États-Unis, 59405
- Recrutement
- Benefis Sletten Cancer Institute
-
Chercheur principal:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Numéro de téléphone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Kalispell, Montana, États-Unis, 59901
- Suspendu
- Logan Health Medical Center
-
Missoula, Montana, États-Unis, 59804
- Recrutement
- Community Medical Center
-
Chercheur principal:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Numéro de téléphone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
-
Nebraska
-
Bellevue, Nebraska, États-Unis, 68123
- Recrutement
- Nebraska Medicine-Bellevue
-
Contact:
- Site Public Contact
- Numéro de téléphone: 402-559-6941
- E-mail: unmcrsa@unmc.edu
-
Chercheur principal:
- Snegha Ananth
-
Omaha, Nebraska, États-Unis, 68198
- Recrutement
- University of Nebraska Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 402-559-6941
- E-mail: unmcrsa@unmc.edu
-
Chercheur principal:
- Snegha Ananth
-
Omaha, Nebraska, États-Unis, 68118
- Recrutement
- Nebraska Medicine-Village Pointe
-
Contact:
- Site Public Contact
- Numéro de téléphone: 402-559-5600
-
Chercheur principal:
- Snegha Ananth
-
-
New York
-
Buffalo, New York, États-Unis, 14263
- Recrutement
- Roswell Park Cancer Institute
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-767-9355
- E-mail: askroswell@roswellpark.org
-
Chercheur principal:
- Alex Niu
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27710
- Suspendu
- Duke University Medical Center
-
-
North Dakota
-
Fargo, North Dakota, États-Unis, 58103
- Recrutement
- Essentia Health Cancer Center-South University Clinic
-
Contact:
- Site Public Contact
- Numéro de téléphone: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Chercheur principal:
- Bret E. Friday
-
-
Ohio
-
Canton, Ohio, États-Unis, 44710
- Recrutement
- Aultman Health Foundation
-
Contact:
- Site Public Contact
- Numéro de téléphone: 330-363-7274
- E-mail: ClinicalReserachDept@aultman.com
-
Chercheur principal:
- Aarthi Rajkumar
-
Cincinnati, Ohio, États-Unis, 45219
- Recrutement
- University of Cincinnati Cancer Center-UC Medical Center
-
Chercheur principal:
- Tahir Latif
-
Contact:
- Site Public Contact
- Numéro de téléphone: 513-584-7698
- E-mail: cancer@uchealth.com
-
Columbus, Ohio, États-Unis, 43210
- Recrutement
- Ohio State University Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-293-5066
- E-mail: Jamesline@osumc.edu
-
Chercheur principal:
- Kathryn Lurain
-
West Chester, Ohio, États-Unis, 45069
- Recrutement
- University of Cincinnati Cancer Center-West Chester
-
Chercheur principal:
- Tahir Latif
-
Contact:
- Site Public Contact
- Numéro de téléphone: 513-584-7698
- E-mail: cancer@uchealth.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73104
- Suspendu
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Hood River, Oregon, États-Unis, 97031
- Recrutement
- Providence Hood River Memorial Hospital
-
Chercheur principal:
- Alison K. Conlin
-
Contact:
- Site Public Contact
- Numéro de téléphone: 503-215-1979
- E-mail: canrsrchstudies@provdience.org
-
Newberg, Oregon, États-Unis, 97132
- Recrutement
- Providence Newberg Medical Center
-
Chercheur principal:
- Alison K. Conlin
-
Contact:
- Site Public Contact
- Numéro de téléphone: 503-215-2614
- E-mail: CanRsrchStudies@providence.org
-
Oregon City, Oregon, États-Unis, 97045
- Recrutement
- Providence Willamette Falls Medical Center
-
Chercheur principal:
- Alison K. Conlin
-
Contact:
- Site Public Contact
- Numéro de téléphone: 503-215-2614
- E-mail: CanRsrchStudies@providence.org
-
Portland, Oregon, États-Unis, 97213
- Recrutement
- Providence Portland Medical Center
-
Chercheur principal:
- Alison K. Conlin
-
Contact:
- Site Public Contact
- Numéro de téléphone: 503-215-2614
- E-mail: CanRsrchStudies@providence.org
-
Portland, Oregon, États-Unis, 97225
- Recrutement
- Providence Saint Vincent Medical Center
-
Chercheur principal:
- Alison K. Conlin
-
Contact:
- Site Public Contact
- Numéro de téléphone: 503-215-2614
- E-mail: CanRsrchStudies@providence.org
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Recrutement
- Thomas Jefferson University Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 215-600-9151
- E-mail: ONCTrialNow@jefferson.edu
-
Chercheur principal:
- Michael Wysota
-
-
Vermont
-
Burlington, Vermont, États-Unis, 05401
- Recrutement
- University of Vermont Medical Center
-
Chercheur principal:
- James N. Gerson
-
Contact:
- Site Public Contact
- Numéro de téléphone: 802-656-4101
- E-mail: rpo@uvm.edu
-
Burlington, Vermont, États-Unis, 05405
- Recrutement
- University of Vermont and State Agricultural College
-
Chercheur principal:
- James N. Gerson
-
Contact:
- Site Public Contact
- Numéro de téléphone: 802-656-8990
- E-mail: rpo@uvm.edu
-
-
Virginia
-
Charlottesville, Virginia, États-Unis, 22908
- Recrutement
- University of Virginia Cancer Center
-
Chercheur principal:
- Craig A. Portell
-
Contact:
- Site Public Contact
- Numéro de téléphone: 434-243-6303
- E-mail: uvacancertrials@hscmail.mcc.virginia.edu
-
Richmond, Virginia, États-Unis, 23298
- Recrutement
- VCU Massey Comprehensive Cancer Center
-
Chercheur principal:
- Bruce O. Hough
-
Contact:
- Site Public Contact
- Numéro de téléphone: 804-628-6430
- E-mail: CTOclinops@vcu.edu
-
-
Washington
-
Seattle, Washington, États-Unis, 98122
- Recrutement
- Swedish Medical Center-First Hill
-
Chercheur principal:
- Alison K. Conlin
-
Contact:
- Site Public Contact
- Numéro de téléphone: 206-215-2343
- E-mail: PCRC-NCORP@Swedish.org
-
-
Wisconsin
-
Ashland, Wisconsin, États-Unis, 54806
- Recrutement
- Duluth Clinic Ashland
-
Contact:
- Site Public Contact
- Numéro de téléphone: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Chercheur principal:
- Bret E. Friday
-
Green Bay, Wisconsin, États-Unis, 54301
- Recrutement
- Saint Vincent Hospital Cancer Center Green Bay
-
Chercheur principal:
- Brian L. Burnette
-
Contact:
- Site Public Contact
- Numéro de téléphone: 920-433-8889
- E-mail: WI_research_admin@hshs.org
-
Green Bay, Wisconsin, États-Unis, 54303
- Recrutement
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
Chercheur principal:
- Brian L. Burnette
-
Contact:
- Site Public Contact
- Numéro de téléphone: 920-433-8889
- E-mail: wi_research_admin@hshs.org
-
Janesville, Wisconsin, États-Unis, 53548
- Recrutement
- Mercyhealth Hospital and Cancer Center - Janesville
-
Contact:
- Site Public Contact
- Numéro de téléphone: 608-756-6871
- E-mail: oncologyclinicaltrials@mhemail.org
-
Chercheur principal:
- Emily G. Robinson
-
La Crosse, Wisconsin, États-Unis, 54601
- Recrutement
- Gundersen Lutheran Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 608-775-2385
- E-mail: cancerctr@gundersenhealth.org
-
Chercheur principal:
- Kurt Oettel
-
Madison, Wisconsin, États-Unis, 53792
- Recrutement
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Chercheur principal:
- Priyanka Pophali
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-622-8922
- E-mail: clinicaltrials@cancer.wisc.edu
-
Madison, Wisconsin, États-Unis, 53718
- Recrutement
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Chercheur principal:
- Priyanka Pophali
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-622-8922
- E-mail: clinicaltrials@cancer.wisc.edu
-
Menomonee Falls, Wisconsin, États-Unis, 53051
- Recrutement
- Froedtert Menomonee Falls Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 262-257-5100
-
Chercheur principal:
- Kaitlin Annunzio
-
Milwaukee, Wisconsin, États-Unis, 53226
- Recrutement
- Medical College of Wisconsin
-
Contact:
- Site Public Contact
- Numéro de téléphone: 414-805-3666
-
Chercheur principal:
- Kaitlin Annunzio
-
Mukwonago, Wisconsin, États-Unis, 53149
- Recrutement
- ProHealth D N Greenwald Center
-
Contact:
- Site Public Contact
- E-mail: research.institute@phci.org
-
Chercheur principal:
- Timothy R. Wassenaar
-
New Berlin, Wisconsin, États-Unis, 53151
- Recrutement
- Froedtert and MCW Moorland Reserve Health Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 414-805-0505
-
Chercheur principal:
- Kaitlin Annunzio
-
Oak Creek, Wisconsin, États-Unis, 53154
- Recrutement
- Drexel Town Square Health Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 414-805-0505
-
Chercheur principal:
- Kaitlin Annunzio
-
Oconomowoc, Wisconsin, États-Unis, 53066
- Recrutement
- ProHealth Oconomowoc Memorial Hospital
-
Chercheur principal:
- Timothy R. Wassenaar
-
Contact:
- Site Public Contact
- Numéro de téléphone: 262-928-7878
-
Oconto Falls, Wisconsin, États-Unis, 54154
- Recrutement
- Saint Vincent Hospital Cancer Center at Oconto Falls
-
Chercheur principal:
- Brian L. Burnette
-
Contact:
- Site Public Contact
- Numéro de téléphone: 920-433-8889
- E-mail: WI_research_admin@hshs.org
-
Sheboygan, Wisconsin, États-Unis, 53081
- Recrutement
- Saint Vincent Hospital Cancer Center at Sheboygan
-
Chercheur principal:
- Brian L. Burnette
-
Contact:
- Site Public Contact
- Numéro de téléphone: 920-433-8889
- E-mail: wi_research_admin@hshs.org
-
Sheboygan, Wisconsin, États-Unis, 53081
- Recrutement
- Sheboygan Physicians Group
-
Chercheur principal:
- Brian L. Burnette
-
Contact:
- Site Public Contact
- Numéro de téléphone: 920-433-8889
- E-mail: wi_research_admin@hshs.org
-
Spooner, Wisconsin, États-Unis, 54801
- Recrutement
- Essentia Health-Spooner Clinic
-
Contact:
- Site Public Contact
- Numéro de téléphone: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Chercheur principal:
- Bret E. Friday
-
Sturgeon Bay, Wisconsin, États-Unis, 54235-1495
- Recrutement
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Chercheur principal:
- Brian L. Burnette
-
Contact:
- Site Public Contact
- Numéro de téléphone: 920-433-8889
- E-mail: wi_research_admin@hshs.org
-
Superior, Wisconsin, États-Unis, 54880
- Recrutement
- Essentia Health Saint Mary's Hospital - Superior
-
Chercheur principal:
- Bret E. Friday
-
Contact:
- Site Public Contact
- Numéro de téléphone: 701-364-6272
-
Waukesha, Wisconsin, États-Unis, 53188
- Recrutement
- UW Cancer Center at ProHealth Care
-
Chercheur principal:
- Timothy R. Wassenaar
-
Contact:
- Site Public Contact
- Numéro de téléphone: 262-928-5539
- E-mail: Chanda.miller@phci.org
-
West Bend, Wisconsin, États-Unis, 53095
- Recrutement
- Froedtert West Bend Hospital/Kraemer Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 414-805-0505
-
Chercheur principal:
- Kaitlin Annunzio
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Patient must be ≥ 18 years of age
-
Patient must have histologically or cytologically confirmed aggressive B-cell lymphoma as follows:
-
Cohort 1: CD10-negative DLBCL, which includes:
- CD10-negative non-GCB DLBCL, not otherwise specified (NOS) (i.e., CD10-/BCL6- or CD10-/BCL6+/MUM1+ DLBCL)
- CD10-negative GCB DLBCL, NOS (i.e., CD10-/BCL6+/MUM1- DLBCL)
- CD10-negative HGBCL with MYC and BCL6 (without BCL2) translocations (HGBCL-DH-BCL6)
- CD10-negative HGBCL, NOS (without MYC and BCL2 translocations)
- CD10-negative T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) OR
-
Cohort 2: CD10-positive or negative HGBCL with MYC and BCL2 rearrangements (with or without BCL6 rearrangement) (HGBCL-DH-BCL2)
- NOTE: The site principal investigator must review and verify the pathology report findings to ensure the patient is eligible and is assigned to the respective cohort at the time of registration
-
-
Patient must have relapsed and/or refractory disease after at least 1 prior anthracycline and anti-CD20 antibody-containing regimen
-
Patient must not have confirmed or suspected primary mediastinal large B-cell lymphoma (PMBL)
-
Patient must not be pregnant due to the potential harm to an unborn fetus with the treatment regimens being used.
- All patients of childbearing potential must have a serum or urine study with a sensitivity of at least 25 mIU/mL within 14 days prior to registration to rule out pregnancy and again within 24 hours prior to starting cycle 1 day 1 of treatment.
- A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patients of childbearing potential must not expect to conceive children by abstaining from sexual intercourse or by using accepted and effective methods of contraception throughout the entire duration of protocol treatment, including during dose interruptions, and for 6 months after the last dose of protocol treatment. Male patients must not father children by abstaining from sexual intercourse or by using a condom during sexual contact with pregnant partners or partners of childbearing potential throughout the entire duration of protocol treatment, including dose interruptions, and for 6 months after the last dose of protocol treatment even if they have had a successful vasectomy
-
Male patients must agree to not donate semen or sperm during the entire duration of protocol treatment or for at least 28 days after the last dose of lenalidomide
-
Patient must agree to abstain from breastfeeding during the entire duration of protocol treatment and for at least 6 months after the last dose of protocol treatment
-
Patient must agree to abstain from donating blood during the entire duration of protocol treatment and for at least 28 days after the last dose of lenalidomide
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Absolute neutrophil count (ANC) ≥ 1,000/mcL without requirement for granulocyte colony stimulating factor (G-CSF) support (obtained ≤ 7 days prior to registration)
-
Hemoglobin ≥ 8 g/dL (obtained ≤ 7 days prior to registration)
-
Platelets ≥ 75,000/mcL without requirement for platelet transfusion support (obtained ≤ 7 days prior to registration)
-
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (or ≤ 3.0 x institutional ULN for patients with documented Gilberts syndrome) (obtained ≤ 7 days prior to registration)
-
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3.0 x institutional ULN (obtained ≤ 7 days prior to registration)
-
Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 30 mL/min/1.73 m^2 (estimated by Cockcroft-Gault method or measured) (obtained ≤ 7 days prior to registration)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patient must not have confirmed or suspected primary DLBCL of the central nervous system (CNS) (PCNSL)
-
Patients with history of secondary CNS lymphoma (SCNSL) are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patient must not have taken or require warfarin or other strong CYP3A inhibitors or inducers within 7 days prior to registration.
- NOTE: Antiplatelet agents, other anticoagulants aside from warfarin, as well as mild or moderate CYP3A inhibitors or inducers are permitted on study but should be used with caution
-
Patient must not have an uncontrolled intercurrent illness that would interfere with the safety or efficacy assessment of this protocol
-
Patient must not have evidence of an active infection at the time of registration
-
Patient must not have the following current or prior anti-cancer treatment:
-
Any chemotherapy, targeted therapy, anti-cancer antibodies, antibody-drug conjugates, or bi-specific antibodies received within 2 weeks prior to registration
- NOTE: Short courses of corticosteroids or palliative external beam radiation therapy (XRT) prior to registration are permitted
-
More than 3 prior lines of cytotoxic chemotherapy, excluding targeted therapy, anti-cancer antibodies, antibody-drug conjugates, bi-specific antibodies, and radio- or toxin-immunoconjugates
- NOTE: Cytoreductive chemotherapy followed by autologous stem cell transplant (ASCT) counts as 1 line of cytotoxic therapy. Similarly, cytoreductive chemotherapy (either pre-T-cell collection or as bridging therapy) followed by pre-conditioning therapy/chimeric antigen receptor T-cell (CAR-T) counts as 1 line of therapy, as long as no disease progression occurs between interventions. For both therapies, if progressive disease is documented between 2 distinct regimens, then they should be counted as 2 lines of cytotoxic chemotherapy
-
Radio- or toxin-immunoconjugates within 10 weeks prior to registration
-
Previous treatment with more than one of the following study agents: venetoclax (or another BCL2 inhibitor), ibrutinib (or another BTK inhibitor), or lenalidomide (or another immunomodulatory imide drug [IMiD])
-
Prior autologous stem cell transplant (ASCT), chimeric antigen receptor T-cell (CAR-T) therapy, or allogeneic stem cell (or other organ) transplant within 3 months prior to registration
-
Any evidence of active graft-versus-host disease or requirement for immunosuppressants within 28 days prior to registration
- NOTE: In addition, patient must have recovered (i.e., ≤ grade 1 or baseline) from all adverse events due to previously administered anti-cancer treatment, surgery, or procedure
- NOTE: Exceptions to this include events not considered to place the patient at unacceptable risk of participation in the opinion of the treating investigator (i.e., alopecia)
-
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
-
Patient must have adequate formalin fixed paraffin embedded (FFPE) tumor tissue specimen from the initial diagnostic biopsy or on-study repeat tumor tissue biopsy for molecular analysis
- NOTE: Excisional tumor biopsy is preferred. Core needle biopsies will be considered adequate if there is enough tissue for the mandatory molecular analysis. Submission of an entire FFPE tumor block is preferred, but if unavailable 10 x 10um FFPE scrolls may be submitted as an alternative. If adequate archived FFPE tumor tissue is unavailable, the patient must be willing to undergo research biopsy for molecular analysis
-
Patient must have measurable disease
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Treatment (ViPOR)
Patients receive venetoclax PO QD on days 2-14, ibrutinib PO QD on days 1-14, prednisone PO QD on days 1-7, obinutuzumab IV on days 1 and 2, and Revlimid PO QD on days 1-14 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, PET, CT and/or MRI and optional tumor biopsy and bone marrow aspiration and biopsy throughout the study. |
Given PO
Autres noms:
Given PO
Autres noms:
Undergo blood sample collection
Autres noms:
Undergo CT
Autres noms:
Undergo MRI
Autres noms:
Undergo bone marrow aspiration and biopsy Undergo bone marrow aspiration and biopsy
Autres noms:
Given PO
Autres noms:
Undergo PET
Autres noms:
Given PO
Autres noms:
Given IV
Autres noms:
Undergo optional tumor biopsy
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Complete response (CR) rate (CD10-negative diffuse large B cell lymphoma [DLBCL] and high grade B-cell lymphoma with MYC and BCL2 with or without BCL6 rearrangements [HGBCL-DH-BCL2])
Délai: Up to 5 years
|
Will be assessed using the Lugano Classification and will be defined as the complete disappearance of all detectable clinical evidence of disease, and disease-related symptoms if present prior to therapy. |
Up to 5 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
CR rate (CD10-negative activated B-cell [ABC] and non-ABC DLBCL)
Délai: Up to 5 years
|
Estimates will be presented with 90% confidence intervals. Frequency and proportion will be used to describe variables on the nominal/ordinal scale, and measures of dispersion for interval/ratio variables. Logistic/linear regression will be performed for binary/continuous endpoints variables. |
Up to 5 years
|
|
Overall response rate
Délai: Up to 5 years
|
Estimates will be presented with 90% confidence intervals. Frequency and proportion will be used to describe variables on the nominal/ordinal scale, and measures of dispersion for interval/ratio variables. Logistic/linear regression will be performed for binary/continuous endpoints variables. |
Up to 5 years
|
|
Duration of response (DOR)
Délai: From the documented beginning of response to the time of relapse up to 10 years
|
Estimates will be presented with 90% confidence intervals. Kaplan-Meier method will be used to visualize DOR. Frequency and proportion will be used to describe variables on the nominal/ordinal scale, and measures of dispersion for interval/ratio variables. Logistic/linear regression will be performed for binary/continuous endpoints variables. |
From the documented beginning of response to the time of relapse up to 10 years
|
|
Event-free survival (EFS)
Délai: From study entry to any treatment failure including discontinuation of treatment for any reason, such as disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death up to 10 years
|
Estimates will be presented with 90% confidence intervals. Kaplan-Meier method will be used to visualize EFS. Frequency and proportion will be used to describe variables on the nominal/ordinal scale, and measures of dispersion for interval/ratio variables. Multivariable analysis will be performed with Cox PH model and logistic/linear regression will be performed for binary/continuous endpoints variables. |
From study entry to any treatment failure including discontinuation of treatment for any reason, such as disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death up to 10 years
|
|
Time of progression (TTP)
Délai: From study entry until lymphoma progression or death due to lymphoma up to 10 years
|
Estimates will be presented with 90% confidence intervals. Kaplan-Meier method will be used to visualize TTP. Frequency and proportion will be used to describe variables on the nominal/ordinal scale, and measures of dispersion for interval/ratio variables. Multivariable analysis will be performed with Cox PH model and logistic/linear regression will be performed for binary/continuous endpoints variables. |
From study entry until lymphoma progression or death due to lymphoma up to 10 years
|
|
Progression-free survival (PFS)
Délai: From entry onto study until lymphoma progression or death from any cause up to 10 years
|
Estimates will be presented with 90% confidence intervals. Kaplan-Meier method will be used to visualize PFS. Frequency and proportion will be used to describe variables on the nominal/ordinal scale, and measures of dispersion for interval/ratio variables. Logistic/linear regression will be performed for binary/continuous endpoints variables. |
From entry onto study until lymphoma progression or death from any cause up to 10 years
|
|
Overall survival (OS)
Délai: From date of study entry to date of death up to 10 years
|
Estimates will be presented with 90% confidence intervals. Kaplan-Meier method will be used to visualize OS. Frequency and proportion will be used to describe variables on the nominal/ordinal scale, and measures of dispersion for interval/ratio variables. Logistic/linear regression will be performed for binary/continuous endpoints variables. |
From date of study entry to date of death up to 10 years
|
|
Incidence of adverse events for patients who are CD10-negative ABC DLBCL, and CD10-negative non-ABC (i.e., unclassified or germinal center B-cell) DLBCL, and CD10-positive or negative HGBCL-DH-BCL2
Délai: Up to 30 days after last dose of study treatment
|
Toxicity data will be pooled for tabulation and analysis. |
Up to 30 days after last dose of study treatment
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Christopher J Melani, ECOG-ACRIN Cancer Research Group
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs
- Maladies du système immunitaire
- Tumeurs par type histologique
- Maladies lymphatiques
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Lymphome non hodgkinien
- Lymphome à cellules B
- Lymphome
- Maladies hémiques et lymphatiques
- Lymphome diffus à grandes cellules B
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Techniques d'investigation
- Techniques de laboratoire clinique
- Techniques et procédures de diagnostic
- Diagnostic
- Procédures chirurgicales, opératoires
- Techniques cytologiques
- Cytodiagnostic
- Acides carboxyliques
- Composés polycycliques
- Pipéridines
- Prégnades
- Grossesse
- Stéroïdes
- Composés à anneau fusionné
- Techniques de diagnostic, chirurgicale
- Techniques de chimie, analytique
- Analyse du spectre
- Grossissements
- Phtalimides
- Acides phtaliques
- Acides, carbocyclique
- Pipéridones
- Isoindoles
- Lénalidomide
- Prednisone
- Biopsie
- Manipulation des échantillons
- Spectroscopie de résonance magnétique
- vénitoclax
- obinutuzumab
- ibrutinib
- deltacortene
- prednylidene
Autres numéros d'identification d'étude
- NCI-2024-08642
- U10CA180820 (Subvention/contrat des NIH des États-Unis)
- NCI-2024-08642 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
- EA4231 (Autre identifiant: CTEP)
- EA4231 (Autre identifiant: ECOG-ACRIN Cancer Research Group)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .